Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
The Lancet Neurology
Fecha de publicación: April 2020
DOI: https://doi.org/10.1016/S1474-4422(20)30067-3
Autores: Anna He, MBBS., Bernd Merkel, PhD., James William L Brown, PhD., Lana Zhovits Ryerson, MD., Ilya Kister, MD., Charles B Malpas, PhD., et al.
Background: High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore aimed to compare long-term disability outcomes between patients who started high-efficacy therapies within 2 years of disease onset with those who started 4–6 years after disease onset.
